ABTECT - Maintenance

Market
100%75%50%25%0%Apr 26 • YES 54.0%Apr 26
Trade

Will this trial meet its primary endpoint?

Paper Trading
Create account to trade
DetailsModel PositionsModel SnapshotsOracle
Primary Completion
4/1/26
Study Completion
5/1/30
Sponsor
Abivax S.A.
Ticker
$ABVX
Type
Phase 3
Trial Status
Active Not Recruiting
Trial Size
1,116
NCT
NCT05535946
Trial Description
Randomized, double-blind, multicenter Phase 3 study evaluating long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as maintenance therapy in subjects with moderately to severely active ulcerative colitis. The study enrolls subjects who completed prior induction studies ABX464-105 or ABX464-106 and includes a 44-week maintenance phase followed by a long-term extension.